Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;44(1 suppl):10-14.
doi: 10.1177/0300060515598902.

Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis

Giulia Ganzetti  1 , Anna Campanati  2 , Andrea Santarelli  3 , Davide Sartini  3 , Elisa Molinelli  1 , Valerio Brisigotti  1 , Giulia Di Ruscio  3 , Ivan Bobyr  1 , Monica Emanuelli  3 , Annamaria Offidani  1
Affiliations

Salivary interleukin-1β: Oral inflammatory biomarker in patients with psoriasis

Giulia Ganzetti et al. J Int Med Res. 2016 Sep.

Abstract

Objective: To evaluate salivary interleukin (IL)-1β levels in patients with psoriasis, before and after treatment with tumour necrosis factor (TNF)-α inhibitors.

Methods: In this pilot study, salivary secretions were collected from patients with psoriasis and untreated healthy control subjects at baseline, and from patients after 12 weeks' treatment with TNF-α inhibitors. IL-1β levels were determined in saliva samples via enzyme-linked immunosorbent assays, undertaken before and after TNF-α inhibitor treatment. Psoriasis-specific analysis of disease severity and activity were also undertaken.

Results: At baseline, patients (n = 25) had significantly higher salivary IL1β levels than controls (n = 20). In patients with psoriasis, TNF-α inhibitor treatment resulted in significantly reduced IL1β levels compared with baseline, but IL1β levels remained significantly higher than in control subjects even after treatment. There was a positive correlation between IL-1β levels, psoriasis activity and disease index score after TNF-α inhibitor treatment.

Conclusion: Saliva is a valid noninvasive tool for monitoring inflammation in psoriasis. TNF-α inhibitor treatments appear to interfere with the oral inflammatory process in patients with psoriasis.

Keywords: IL-1β; TNF-α inhibitor treatment; oral biomarker; psoriasis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Salivary interleukin (IL)-1 β levels in patients with psoriasis and controls. Tumour necrosis factor-α inhibitor treatment significantly reduced IL1β levels, compared with baseline (T0); however, IL1β levels remained significantly higher in patients with psoriasis than in healthy controls at the end of the 12-week treatment period (T12); ***P < 0.001; Kruskal–Wallis test.
See this image and copyright information in PMC

References

    1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535–546. - PubMed
    1. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5–21. - PubMed
    1. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152–155. - PubMed
    1. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology 2008; 217: 27–37. - PubMed
    1. Preus HR, Khanifam P, Kolltveit K, et al. Periodontitis in psoriasis patients: a blinded, case-controlled study. Acta Odontol Scand 2010; 68: 165–170. - PubMed